Biotech Values

[DewDiligence]

EPRS inks FoB collaboration with China’s Livzon Mabpharm:

http://finance.yahoo.com/news/epirus-livzon-mabpharm-inc-enter-120000117.html

EPIRUS Biopharmaceuticals, Inc., a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced today that it has signed a royalty-bearing, multi-product collaboration agreement with Livzon Mabpharm Inc., a Chinese biotechnology company focused on the development, manufacture, and sale of antibody-based drugs.

…Under the terms of the agreement, EPIRUS and Livzon will work together to develop, manufacture, and commercialize up to five biosimilar products. The first collaboration product is EPIRUS’ Remicade biosimilar BOW015 (infliximab), which was recently approved in India [see below]. Livzon will conduct any additional development work necessary for the approval of BOW015 in China and Taiwan. Livzon will also serve as the preferred supplier of BOW015 in these territories, following a transfer of EPIRUS’ SCALE manufacturing platform. Livzon will be responsible for all commercialization activities in its territories.

Epirus went public via a reverse merger with ZLCS announced in Apr 2014 (#msg-100707725). EPRS has a collaboration with Ranbaxy (#msg-95745192) to develop a Remicade FoB for countries in South East Asia, North Africa, and India (where it is already approved).